Company profilePharmaceutical#500 of 1,318 in Pakistan✓ No DRAP alerts

SHAZALS PHARMACEUTICALS

Pharmaceutical company · 27 brands · 25 molecules

Ranked #59 of 74 companies in Pain Management

27 registered products 16 pharmaceutical brands 25 distinct molecules 0 DRAP alerts

Company overview

27
registered products
16
pharmaceutical brands
25
distinct molecules
2
therapeutic classes
0
DRAP alerts

SHAZALS PHARMACEUTICALS is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 27 product registrations across 25 distinct molecules. Its portfolio is concentrated in Pain Management and Muscle Relaxant. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by SHAZALS

1 product matched in our catalogue — each with its observed price and DRAP approved ceiling.

Pain Management 1

Top molecules by brand count

Diclofenac3 brands
Tizanidine2 brands
Fusidic Acid2 brands
Cetirizine1 brand
Cephradine1 brand
Artemether1 brand
Meloxicam1 brand
Piroxicam-Beta-Cyclodextrin1 brand

Therapeutic classes

Pain Management · 1Muscle Relaxant · 1

Conditions treated

Pain Killers · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official3 products · Rs 361.11 – Rs 586.84
Servaid1 products · Rs 200 – Rs 200
Median across source: Rs 491.98

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

BIO LABS (PVT) LTD. holds 139 molecules not in this portfolio
000 I.UAmlodipineAprepitantAremetherArtemetherArtesunate
Horizon Pharmaceuticals (Pvt) Limited holds 138 molecules not in this portfolio
000 I.UAcyclovirAlbendazoleAmlodipineAmoxicillinAmoxycillin Base
GENOME PHARMACEUTICALS (PVT) LTD holds 112 molecules not in this portfolio
AcitretinAmlodipineAnastrazoleAnastrozoleAprepitantArtemether

Get the full profile for SHAZALS

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.